About
Profile
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
VALN
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Valneva reports 1H results
- Pfizer, Valneva post Phase 2 booster data for Lyme disease vaccine
- Valneva falls as FDA extends review of chikungunya vaccine
- WHO meeting is set to decide whether to end COVID emergency
- Valneva reports Q1 results
- WHO chief expects COVID emergency to end this year
- Valneva, Pfizer delay end date of Lyme disease vaccine phase 3 trial to 2025
- Valneva GAAP EPS of €1.24, revenue of €361.3M; issues FY23 guidance
- Valneva COVID shot shelf life extended; gets EMA nod for booster; shows efficacy in trials
- Valneva's single-shot chikungunya vaccine VLA1553 gets FDA priority review
- Pfizer, Valneva removes ~50% participants in Lyme disease vaccine trial on violation woes
- Valneva reports FY results; issues FY23 guidance
- Valneva finishes enrolling in phase 3 trial of single-shot chikungunya vaccine in adolescents
- WHO maintains public health emergency on COVID but sees pandemic at 'transition point'
- WHO sets Jan. 27 meeting to decide on COVID emergency
- Valneva stock rises as it seeks FDA approval of single-shot chikungunya vaccine
- WHO chief hopeful COVID emergency will end next year
- Valneva dips as French health authority advises against COVID shot
- Pfizer, Valneva Lyme disease vaccine shows antibodies 6-month after vaccination
- Valneva reports Q3 results; reaffirms FY22 guidance